Senda Biosciences to virtually present at the Chardan 3rd Annual Microbiome Medicines Summit prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
CAMBRIDGE, Mass., Jan. 26, 2021 /PRNewswire/ Senda Biosciences, a therapeutics platform company creating novel categories of medicines based on a new field of science called Intersystems Biology, announced today that it has entered into a strategic collaboration with Nestlé Health Science for the development of novel nutritional therapies for a wide range of metabolic conditions, including obesity and glycemia.
The companies will focus initially on accelerating first-in-human clinical studies on up to three small molecule compounds developed by Senda, leveraging the capabilities of Nestlé Health Science, a global leader in the science of nutrition. The compounds have been rationally designed based on Senda s Intersystems Biology discovery platform, and screened through Senda s proprietary bioassays for their potential to improve metabolic health. In preclinical studies these compounds have shown the ability to achieve sustained reducti
Share this article
Share this article
CAMBRIDGE, Mass., Jan. 7, 2021 /PRNewswire/ Senda Biosciences, a Flagship Pioneering company creating novel categories of medicines based on Intersystems Biology, today announced the formation of its Scientific Advisory Board (SAB). Senda s SAB is composed of leading experts across immunology, microbiology, biochemistry, and neurology, and will collaborate with Senda s leadership to support and advance the new research discipline of Intersystems Biology. This discipline focuses on how molecular connections among botanical, bacterial, and human cells coevolved over millennia define health and disease. We are thrilled to have attracted some of the brightest minds in their fields to our SAB, says Guillaume Pfefer, PhD, chief executive officer of Senda. The deep expertise of the SAB will be pivotal to the advancement of our novel approach to medicines development, rooted in an unparalleled understanding of interspecies molecular connections.